Bulletin

Roche

Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness

December 13, 2024

WHO

New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

December 10, 2024

Roche

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

December 9, 2024

WHO

WHO supports Democratic Republic of the Congo reinforce efforts to diagnose disease in remote area

December 6, 2024

WHO

Oropouche virus disease - Region of the Americas

December 6, 2024

Roche

FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

December 5, 2024

WHO

WHO announces first prequalification of a tuberculosis diagnostic test

December 5, 2024

Press Information Bureau

Union Health Minister Shri Jagat Prakash Nadda inaugurates World AIDS Day 2024 event in the presence of Dr. Mohan Yadav, Chief Minister of Madhya Pradesh in Indore, Madhya Pradesh

December 1, 2024

Press Information Bureau

Ministry of Health and Family Welfare’s ‘One Health’ Pavilion Receives ’Special Appreciation Medal’ at IITF 2024

November 28, 2024

Roche

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

November 26, 2024

Roche

Roche reports update on Phase III SKYSCRAPER-01 study results

November 26, 2024

WHO

WHO adds LC16m8 mpox vaccine to Emergency Use Listing

November 19, 2024

WHO

WHO and partners rally cervical cancer elimination efforts

November 17, 2024

< 1 … 19 20 21 22 23 24 25 26 27 … 94 >

Bulletin

Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness

Drowning deaths decline globally but the most vulnerable remain at risk

New WHO report reveals governments deprioritizing health spending

Over 1 in 5 adults worldwide has a genital herpes infection

New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

WHO supports Democratic Republic of the Congo reinforce efforts to diagnose disease in remote area

Oropouche virus disease - Region of the Americas

FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

WHO announces first prequalification of a tuberculosis diagnostic test

Union Health Minister Shri Jagat Prakash Nadda inaugurates World AIDS Day 2024 event in the presence of Dr. Mohan Yadav, Chief Minister of Madhya Pradesh in Indore, Madhya Pradesh

Ministry of Health and Family Welfare’s ‘One Health’ Pavilion Receives ’Special Appreciation Medal’ at IITF 2024

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Roche reports update on Phase III SKYSCRAPER-01 study results

WHO adds LC16m8 mpox vaccine to Emergency Use Listing

WHO and partners rally cervical cancer elimination efforts

Company

Resources